Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study
DOI:
https://doi.org/10.2340/actadv.v104.18638Keywords:
Atopic dermatitis, cardiovascular, JAK inhibitor, malignancy, prevalence, risk factorAbstract
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis. This cross-sectional study used the Danish national registers and Danish Skin Cohort to assess the prevalence of risk factors that potentially impact choice of treatment with oral Janus kinase inhibitors in adult patients with atopic dermatitis. From the Danish national registers and Danish Skin Cohort, 18,618 and 3,573 adults with atopic dermatitis, respectively, were identified. Half of the patients (49.5%) had, at some point, been registered to have at least 1 risk factor that could impact treatment with oral Janus kinase inhibitors. Non-modifiable risk factors recorded were cancer (5.6%), major adverse cardiovascular events (2.6%), venous thromboembolism (2.0%), smoking history (15.6%), and age ≥ 65 years (12.4%). Among patients ≥ 65 years of age, the mean (standard deviation) number of risk factors were 3 (1.4), and almost half of these patients had, at some point, been registered to have 1 or more non-modifiable risk factors in addition to their age. In conclusion, risk factors that may impact treatment with oral Janus kinase inhibitors were frequent in Danish adults with atopic dermatitis, especially among older individuals. Dermatologists need support and continuously updated long-term safety data when risk-evaluating patients with atopic dermatitis prior to initiation of advanced
Downloads
References
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 2022; 18: 301-304.
https://doi.org/10.1038/s41584-022-00767-7 DOI: https://doi.org/10.1038/s41584-022-00767-7
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386: 316-326.
https://doi.org/10.1056/NEJMoa2109927 DOI: https://doi.org/10.1056/NEJMoa2109927
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. [Accessed Feb 13, 2023] Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther 2023; 10: 201-223.
https://doi.org/10.1007/s40744-022-00505-1 DOI: https://doi.org/10.1007/s40744-022-00505-1
EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2023. [Accessed Feb 13, 2023] Available from: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki.
Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ Open 2019; 9: e028116.
https://doi.org/10.1136/bmjopen-2018-028116 DOI: https://doi.org/10.1136/bmjopen-2018-028116
Haugaard JH, Dreyer L, Ottosen MB, Gislason G, Kofoed K, Egeberg A. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: a Danish nationwide cohort study. J Am Acad Dermatol 2021; 84: 930-937.
https://doi.org/10.1016/j.jaad.2020.12.013 DOI: https://doi.org/10.1016/j.jaad.2020.12.013
Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: 1-9.
https://doi.org/10.1136/bmj.d124 DOI: https://doi.org/10.1136/bmj.d124
Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 2016; 136: 93-98.
https://doi.org/10.1038/JID.2015.350 DOI: https://doi.org/10.1038/JID.2015.350
Canning M, Jørgensen S, Noer M, Nørholk L, Lidegaard O, Petersen K. Danish Society of Obstetrics and Gynaecology's guideline. In: hormonal contraception and thromboembolic disease. [in Danish] 2020.
Schmidt SAJ, Vestergaard M, Baggesen LM, Pedersen L, Schønheyder HC, Sørensen HT. Prevaccination epidemiology of herpes zoster in Denmark: quantification of occurrence and risk factors. Vaccine 2017; 35: 5589-5596.
https://doi.org/10.1016/j.vaccine.2017.08.065 DOI: https://doi.org/10.1016/j.vaccine.2017.08.065
Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 1119-1125.e1.
https://doi.org/10.1016/j.jaad.2016.07.017 DOI: https://doi.org/10.1016/j.jaad.2016.07.017
Yousaf M, Ayasse M, Ahmed A, Gwillim EC, Janmohamed SR, Yousaf A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis. Br J Dermatol 2022; 186: 227-235.
https://doi.org/10.1111/bjd.20661 DOI: https://doi.org/10.1111/bjd.20661
Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol 2015; 72: 606-616.e4.
https://doi.org/10.1016/j.jaad.2014.12.013 DOI: https://doi.org/10.1016/j.jaad.2014.12.013
Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol 2018; 19: 821-838.
https://doi.org/10.1007/s40257-018-0383-4 DOI: https://doi.org/10.1007/s40257-018-0383-4
Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis - what does the evidence say? J Allergy Clin Immunol 2023; 151: 1155-1162
https://doi.org/10.1016/j.jaci.2022.12.002 DOI: https://doi.org/10.1016/j.jaci.2022.12.002
Yuan M, Cao WF, Xie XF, Zhou HY, Wu XM. Relationship of atopic dermatitis with stroke and myocardial infarction: a meta-analysis. Medicine (Baltimore) 2018; 97: e13512.
https://doi.org/10.1097/MD.0000000000013512 DOI: https://doi.org/10.1097/MD.0000000000013512
Ascott A, Mulick A, Yu AM, Prieto-Merino D, Schmidt M, Abuabara K, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol 2019; 143: 1821-1829.
https://doi.org/10.1016/j.jaci.2018.11.030 DOI: https://doi.org/10.1016/j.jaci.2018.11.030
Thyssen JP, Halling-Overgaard AS, Andersen YMF, Gislason G, Skov L, Egeberg A. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2018; 178: 1272-1279.
https://doi.org/10.1111/bjd.16215 DOI: https://doi.org/10.1111/bjd.16215
Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol 2022; 158: 1254-1261.
https://doi.org/10.1001/jamadermatol.2022.3516 DOI: https://doi.org/10.1001/jamadermatol.2022.3516
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 2022; 82: 331-343.
https://doi.org/10.1136/ard-2022-222543 DOI: https://doi.org/10.1136/ard-2022-222543
Wu AD, Lindson N, Hartmann-Boyce J, Wahedi A, Hajizadeh A, Theodoulou A, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2022; 8: CD014936.
https://doi.org/10.1002/14651858.CD014936.pub2 DOI: https://doi.org/10.1002/14651858.CD014936.pub2
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors : an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis 2023; 82: 901-910.
https://doi.org/10.1136/ard-2022-223715 DOI: https://doi.org/10.1136/ard-2022-223715
Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther 2022; 39: 4910-4960.
https://doi.org/10.1007/s12325-022-02281-4 DOI: https://doi.org/10.1007/s12325-022-02281-4
Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, et al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv Ther 2023; 40: 1867-1883.
https://doi.org/10.1007/s12325-023-02445-w DOI: https://doi.org/10.1007/s12325-023-02445-w
Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 2019; 71: 1042-1055.
https://doi.org/10.1002/art.40841 DOI: https://doi.org/10.1002/art.40841
Andersen YMF, Egeberg A, Hamann CR, Skov L, Gislason GH, Skaaby T, et al. Poor agreement in questionnaire-based diagnostic criteria for adult atopic dermatitis is a challenge when examining cardiovascular comorbidity. Allergy 2018; 73: 923-931.
https://doi.org/10.1111/all.13360 DOI: https://doi.org/10.1111/all.13360
Kronborg CN, Hallas J, Jacobsen IA. Prevalence, awareness, and control of arterial hypertension in Denmark. J Am Soc Hypertens 2009; 3: 19-24.e2.
https://doi.org/10.1016/j.jash.2008.08.001 DOI: https://doi.org/10.1016/j.jash.2008.08.001
Hoffmann-Petersen N, Lauritzen T, Bech JN, Pedersen EB. High prevalence of hypertension in a Danish population telemedical home measurement of blood pressure in citizens aged 55-64 years in Holstebro county. Am J Hypertens 2016; 29: 439-447.
https://doi.org/10.1093/ajh/hpv116 DOI: https://doi.org/10.1093/ajh/hpv116
Glumer C, Jørgensen T, Borch-Johnsen K, Study I. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Careare 2003; 26: 2335-2340.
https://doi.org/10.2337/diacare.26.8.2335 DOI: https://doi.org/10.2337/diacare.26.8.2335
Bentham J, Di Cesare M, Bilano V, Bixby H, Zhou B, Stevens GA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390: 2627-2642.
https://doi.org/10.1016/S0140-6736(17)32129-3 DOI: https://doi.org/10.1016/S0140-6736(17)32129-3
Ritchie H, Roser M. Our World In Data. [Accessed Mar 23, 2023] Available from: https://ourworldindata.org/obesity
Ritchie H, Roser M. Our World In Data. [Accessed Mar 10, 2023] Available from: https://ourworldindata.org/smoking.
Egeberg A, Griffiths CEM, Williams HC, Andersen YMF, Thyssen JP. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol 2020; 183: 128-138.
https://doi.org/10.1111/bjd.18622 DOI: https://doi.org/10.1111/bjd.18622
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
